Langsam Jeffrey 4

What Happened Jeffrey Langsam, Chief Clinical Officer of Oncology Institute, Inc. (TOI), received a grant of 70,270 restricted stock units (RSUs) on March 27, 2026. The Form 4 reports the acquisition price as $0.00 (award), so the filing shows $0 cash paid at grant. This is a compensation award (an A-code transaction), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-27; Transaction type/code: Award (A).
• Shares/units granted: 70,270 RSUs; reported acquisition price: $0.00.
• Shares owned after the transaction: not specified in the provided filing data.
• Vesting footnote: 1/4 vests on the first anniversary of the vesting commencement date, then the remaining RSUs vest in three equal annual installments, fully vesting on the fourth anniversary, subject to continued service.
• Filing: Form 4 filed 2026-04-01 — after the 2-business-day SEC deadline for a 2026-03-27 transaction (appears to be late).

Context RSUs are time-based compensation that convert into shares only as they vest; they do not represent immediate sales or purchases. Such awards are common for executive compensation and should be viewed as part of pay/retention, not a direct buy/sell signal.